SCHEMBL14770690

SCHEMBL14770690

COc1ccc(C(O)c2nc3cc(OC)ccc3[nH]2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MLKL Q8NB16 2/20 0.52
CHEK2 O96017 1/20 0.45
ALDH1A1 P00352 5/20 0.44
MEN1 O00255 4/20 0.44
KMT2A Q03164 4/20 0.44
MAPT P10636 2/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2C19 P33261 1/20 0.44
TSHR P16473 2/20 0.43
GAA P10253 1/20 0.43
MAPK1 P28482 1/20 0.43
MTNR1B P49286 2/20 0.41
MTNR1A P48039 1/20 0.41
ATM Q13315 1/20 0.40
KDM4E B2RXH2 3/20 0.40
HTT P42858 2/20 0.40
GFER P55789 1/20 0.40
HSD17B10 Q99714 1/20 0.40
PDE10A Q9Y233 2/20 0.40
AXL P30530 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12066577 0.91 MLKL (0.59) MLKLCHEK2ALDH1A1MEN1KMT2A
SCHEMBL14770701 0.91 MLKL (0.49) MLKLCHEK2ALDH1A1MEN1KMT2A
SCHEMBL14770471 0.90 MEN1 (0.55) MLKLCHEK2ALDH1A1MEN1KMT2A
SCHEMBL14770699 0.90 MLKL (0.46) MLKLCHEK2ALDH1A1MEN1KMT2A
SCHEMBL14770697 0.89 MLKL (0.51) MLKLCHEK2MEN1KMT2ACYP1A2
SCHEMBL14770608 0.89 MLKL (0.48) MLKLCHEK2ALDH1A1MEN1KMT2A
SCHEMBL14770470 0.89 MLKL (0.48) MLKLCHEK2ALDH1A1MEN1KMT2A
SCHEMBL12065285 0.89 SCN10A (0.46) MLKLCHEK2ALDH1A1MEN1KMT2A
SCHEMBL14770707 0.89 SCN10A (0.48) MLKLCHEK2ALDH1A1MEN1KMT2A
SCHEMBL14770565 0.86 CHEK2 (0.49) MLKLCHEK2MEN1KMT2AMTNR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096531-B2 Fused imidazole derivative TOA EIYO LTD. (JP) 2015-08-04 US disclosed
US-20130065896-A1 FUSED IMIDAZOLE DERIVATIVE TOA EIYO LTD. (JP) 2013-03-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130065896-A1 FUSED IMIDAZOLE DERIVATIVE CACNA1E, CACNA1G, CACNA1A MLKL 2378/4885CHEK2 1636/4885ALDH1A1 4252/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.